CorMedix Inc. (NYSEAMERICAN: CRMD) has had a rough run in the market this week so far, falling since it hit it’s weekly high on the 25th of February. Nonetheless, with the declines in play, many are wondering if they should buy the dip. Today, we’ll talk about:
- The value proposition offered up by CRMD stock;
- what we’re seeing from the stock; and
- what we’ll be watching for ahead.
The Value Proposition Offered Up By CRMD
As mentioned above, CorMedix is having a rough week in the market this week. However, in some cases, declines can represent opportunities, and many are wondering if that’s the case here.
If you haven’t followed CRMD, the company’s claim to fame is Neutrolin. Neutrolin is a catheter lock solution that is designed to reduce chances of infections associated with intravenous catheters.
The Neutrolin solution is an antimicrobial solution that has been proven through various clinical trials to reduce the risk of intravenous catheter-related infections. To reduce the risk of blood stream infections, various solutions are used on a daily basis. However, study data suggests that Neutrolin could be the superior option.
It’s important to mention that the central venous catheter market is a large one and a growing one. In fact, it is estimated that the market will soon reach over $1 billion annually with a CAGR of more than 5%.
All in all, CRMD seems to be presenting an opportunity through the declines this week. With strong gains presented over the past six months, representing heavy investor interest, a strong product, and a market that is growing, we believe that the growth trend that we’ve seen over the past several months will continue shortly.
What We’re Seeing From The Stock
In the makret, we tend to see ebbs and flows. That’s why so many of the gurus say not to focus on short term trends, but on products, IP and long term ability to grow. At the moment, CorMedix is falling, but we don’t believe that this will last long.
Nonetheless, our partners at Trade Ideas were the first to alert us to the declines. Currently (11:37), CRMD is trading at $1.72 per share after a loss of $0.05 per share or 2.82% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CRMD. In particular, we’re interested in following the story surrounding the company’s continued work to bring its Neutrolin catheter lock solution to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!